Effectiveness of remdesivir for adults with COVID-19

Editor's Note

In this study, funded by the US Department of Veterans Affairs, researchers find that remdesivir probably improves recovery from COVID-19 and reduces serious adverse events and mortality.

This analysis of four randomized trials finds that remdesivir compared with placebo may improve recovery (ARD, 7% to 10%), reduce mortality (ARD, -4% to 1%), reduce serious adverse events (ARD, -6% to -8%), and shorten time to recovery. Recovery may not vary by age, gender, symptom duration, or disease severity.

The researchers also found that a 5-day course of remdesivir provides similar benefits to a 10-day course, with fewer harms and lower cost.

New evidence will be incorporated using living review methods and may alter conclusions, the authors note.